DSIP (Delta Sleep-Inducing Peptide) Reconstitution Calculator
DSIP has published human dosing figures, and not one of them is for the route it is sold for. Every human dose in the literature was given intravenously, in a hospital setting, or in a single study intranasally; the nightly subcutaneous injection that vendors and clinics sell is a route no published human study has used. The figures in the table below are those studies, reported as they were stated and numbered to their papers, not converted into something to inject under the skin. DSIP itself is a nonapeptide, originally isolated from the cerebral venous blood of sleeping rabbits and present endogenously in human plasma and cerebrospinal fluid. It has never been approved by the FDA or the EMA, was investigated pharmaceutically in Europe in the 1980s and 1990s and abandoned, and circulates today as a research chemical. The calculator converts a vial size and a volume of bacteriostatic water into mg/ml and U-100 syringe units, which is arithmetic about the vial and nothing more.
Curated by Dosavy from published literature and regulator labels. Published 11 September 2026, last reviewed 11 September 2026. No clinician reviews this page.
Enter a target dose above to see the draw.
What the evidence says
| Experience | Route | Range | Frequency |
|---|---|---|---|
| Intermediate | Intranasal | 300 mcg[1]The single intranasal human protocol in the corpus: 'deltalicin (daily dose of 0.0003 g of delta sleep-inducing peptide intranasally for two months)' given to 15 insulin-dependent patients with diabetic retinopathy, with visual evoked potentials as the endpoint. This was not a sleep study and not a healthy-adult population; it is recorded because it is the only human dose in the corpus stated as an absolute amount for a self-administrable route. | Once daily |
| Intermediate | Intravenous | 3–4 mg[2][3][4][5][6]Administered intravenously. This is not a subcutaneous dose and not a self-administration protocol. The dose used in essentially all human DSIP work is weight-based (25 nmol/kg body weight, given as a slow intravenous infusion; one study states the equivalent as 25 micrograms/kg over 30 min), which cannot be written as a fixed number without assuming a body weight. The 3 mg and 4 mg figures recorded here are the only absolute total doses stated anywhere in the corpus, from a neuroendocrine study in healthy men in which DSIP was infused intravenously over roughly two hours. A separate anaesthesia study escalated to 25, 50 and 100 nmol/kg as intravenous boluses. Slow injection was described as essential. | Single slow intravenous infusion, in a hospital setting |
- IntermediateIntranasal
300 mcg[1]
Once daily
The single intranasal human protocol in the corpus: 'deltalicin (daily dose of 0.0003 g of delta sleep-inducing peptide intranasally for two months)' given to 15 insulin-dependent patients with diabetic retinopathy, with visual evoked potentials as the endpoint. This was not a sleep study and not a healthy-adult population; it is recorded because it is the only human dose in the corpus stated as an absolute amount for a self-administrable route.
- IntermediateIntravenous
Single slow intravenous infusion, in a hospital setting
Administered intravenously. This is not a subcutaneous dose and not a self-administration protocol. The dose used in essentially all human DSIP work is weight-based (25 nmol/kg body weight, given as a slow intravenous infusion; one study states the equivalent as 25 micrograms/kg over 30 min), which cannot be written as a fixed number without assuming a body weight. The 3 mg and 4 mg figures recorded here are the only absolute total doses stated anywhere in the corpus, from a neuroendocrine study in healthy men in which DSIP was infused intravenously over roughly two hours. A separate anaesthesia study escalated to 25, 50 and 100 nmol/kg as intravenous boluses. Slow injection was described as essential.
Published ranges, reported as the literature states them and numbered to the sources at the foot of this page. Not a recommendation.
Human dosing figures exist and are cited below, but the route does not match how DSIP is actually used. The dominant human dose across the sleep literature is weight-based (25 nmol/kg body weight as a slow intravenous infusion), which this schema cannot represent as a fixed number without assuming a body weight, so the intravenous range records the only absolute totals stated in the corpus. All of this work is from 1981-2009, in single-digit-to-low-double-digit subject counts, with contradictory conclusions. Nothing in the corpus establishes a subcutaneous dose, and the 100-300 mcg subcutaneous nightly figure recorded under community_practice is a market observation with no trial behind it.
DSIP (Delta Sleep-Inducing Peptide) at a glance
- Category
- Sleep / nootropic
- Half-life
- Not established
- Routes
- Subcutaneous, Intranasal, Other
- Regulatory status
- Not approved
- Also sold as
- DSIP, delta sleep-inducing peptide, Deltaran, deltalicin
Mechanism
A nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from the cerebral venous blood of sleeping rabbits, which crosses the blood-brain barrier. It is present endogenously in human plasma and cerebrospinal fluid: plasma DSIP-like immunoreactivity falls significantly at the transition from wakefulness to sleep, in both nocturnal and morning recovery sleep, and follows a diurnal rhythm correlating positively with body temperature. Beyond somnogenic effects it has been described as having opiate-receptor-agonist-like activity, and was used in one series to treat alcohol and opiate withdrawal symptoms. The molecular mechanism of its effect on sleep has never been established, and its endogenous role is correlative rather than demonstrated.
Reconstitution
Sold as lyophilised powder requiring reconstitution before use, with no validated procedure, concentration standard or sterility assurance attached. Nothing in the published human literature describes a self-prepared subcutaneous presentation.
Storage
No approved label defines storage. Supplied as a lyophilised research powder with no pharmaceutical storage standard; the Russian 'Deltaran' preparation is a separate, non-Western product.
Frequency in practice
In the published human literature: a single slow intravenous infusion (route 'other' below), or a daily intranasal dose. In current commercial practice: a single subcutaneous injection nightly before bed, a route no published human study used.
Regulatory
Never approved by the FDA or EMA and not approved as a medicine in North America or Western Europe. DSIP was investigated pharmaceutically in Europe in the 1980s and 1990s and abandoned; DSIP-containing preparations ('Deltaran', 'deltalicin') exist in Russia. It circulates today as a research chemical and as a compounded clinic peptide.
What to know before anything else
Not FDA- or EMA-approved. There is no approved label, no defined safe dose, and no contraindication or interaction information of pharmaceutical standard.
No published human study administered DSIP subcutaneously. Every human dose in the literature was given intravenously, or in one study intranasally. The subcutaneous nightly injection that vendors and clinics sell is an unstudied route, and the intravenous figures below are hospital infusion protocols. They are not doses to inject under the skin.
The efficacy evidence is old and contradictory. A double-blind study in 16 chronic insomniacs concluded that 'short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit' (PMID 1299794), while other small studies from the same era reported clear improvement. Human work on DSIP largely stopped in the 1990s.
In anaesthetised patients, intravenous DSIP significantly increased heart rate, decreased heart-rate variability and, paradoxically for a peptide named after delta sleep, reduced delta rhythm and increased bispectral index during isoflurane anaesthesia (PMID 19142086). Its cardiovascular and autonomic effects are not benign or well characterised.
DSIP has been reported to have opiate-receptor-agonist-like activity and was given to patients in alcohol and opiate withdrawal. Interaction with opioids, sedatives and other CNS depressants has never been studied.
No study has run DSIP for longer than a few weeks. Nightly, indefinite self-administration has no safety data of any kind behind it.
DSIP (Delta Sleep-Inducing Peptide) questions
Is there an established dose for DSIP?
Not for the way it is sold. Human figures exist and are cited below, but the dominant dose across the sleep literature is weight-based and given as a slow intravenous infusion, which this library cannot state as a fixed number without assuming a body weight; the intravenous row records the only absolute totals stated anywhere in the corpus. The single intranasal protocol was a two-month course in patients with diabetic retinopathy, which was not a sleep study and not a healthy-adult population. Nothing in the corpus establishes a subcutaneous dose at all.
Does DSIP actually work for sleep?
The efficacy evidence is old and contradictory. A 1992 double-blind study in sixteen chronic insomniacs (PMID 1299794) found sleep efficiency and latency improved, but its authors concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit. A 1981 controlled clinical study (PMID 6895513) reported acute and delayed effects on sleep behaviour after morning infusions, and other small studies from the same era reported clear improvement. Human work on DSIP largely stopped in the 1990s, so nothing since has settled it.
How does DSIP work?
Nobody has established that. It is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, which crosses the blood-brain barrier and is present endogenously in human plasma and cerebrospinal fluid: plasma DSIP-like immunoreactivity falls significantly at the transition from wakefulness to sleep, in both nocturnal and morning recovery sleep, and follows a diurnal rhythm correlating positively with body temperature. Beyond somnogenic effects it has been described as having opiate-receptor-agonist-like activity, and was used in one series to treat alcohol and opiate withdrawal symptoms. The molecular mechanism of its effect on sleep has never been established, and its endogenous role is correlative rather than demonstrated.
Why is DSIP injected under the skin if no study used that route?
Because that is what the market sells, not because anything was tested. In the published human literature DSIP was infused intravenously in a hospital setting, or given intranasally in one study. Current commercial practice is a single subcutaneous injection nightly before bed, a route no published human study used. The intravenous figures below are hospital infusion protocols, and slow injection was described as essential in that work, so they are not doses to inject under the skin. DSIP is also supplied as a lyophilised research powder with no validated reconstitution procedure, concentration standard or sterility assurance attached, and nothing in the human literature describes a self-prepared subcutaneous presentation.
Is DSIP legal, and is it approved anywhere?
It has never been approved by the FDA or the EMA, and it is not approved as a medicine in North America or Western Europe. DSIP-containing preparations do exist in Russia, sold as Deltaran and deltalicin, which are separate non-Western products. Everywhere else it circulates as a research chemical or a compounded clinic peptide, with no approved label, no defined safe dose, and no contraindication or interaction information of pharmaceutical standard.
What are the safety concerns with DSIP?
The cardiovascular ones are measured rather than theoretical. In a 2009 randomised controlled study of twenty-four anaesthetised patients (PMID 19142086), intravenous DSIP increased heart rate, decreased heart-rate variability and, paradoxically for a peptide named after delta sleep, reduced delta rhythm and increased bispectral index during isoflurane anaesthesia. Its reported opiate-receptor-agonist-like activity means the interaction with opioids, sedatives and other CNS depressants is a real question, and it has never been studied. No study has run DSIP for longer than a few weeks, so nightly indefinite self-administration has no safety data of any kind behind it.
Does DSIP change hormone levels?
Two studies looked and found nothing. A 1995 clinical trial in twenty men (PMID 7777652) infused DSIP intravenously around CRH injections and meals, and saw no effect on ACTH or cortisol secretion. A 1993 controlled study in eight women (PMID 8475226) gave it intravenously and found no influence on growth hormone or prolactin. Those are the hormone endpoints this library holds; any other hormonal claim has no study behind it here.
Every number above, and where it came from
6 sources, numbered where they are used. Each one links to the paper or the label itself, not to a summary of it.
- [1][Using deltalicin for the treatment of patients with diabetic retinopathy]
Eksperimental'naia i klinicheskaia farmakologiia · 2014 · Clinical trial · n=45
- [2]Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion
Psychoneuroendocrinology · 1995 · Clinical trial · n=20
- [3]Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
Neuropsychobiology · 1992 · Randomized controlled trial · n=16
- [4]Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
International journal of clinical pharmacology, therapy, and toxicology · 1981 · Controlled clinical trial
- [5]Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women
Psychoneuroendocrinology · 1993 · Controlled clinical trial · n=8
- [6]Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia
European journal of anaesthesiology · 2009 · Randomized controlled trial · n=24
The rest of the math
- Reconstitution calculatorThe full version of the tool above, with syringe barrel sizes and IU conversion.
- Vial longevityHow many doses a vial holds and the date it runs out.
- Cost per doseVial price against doses drawn, so two vial sizes can be compared honestly.
- Half-life and decayFirst-order clearance, time to steady state, and what remains at a given hour.
Same class as DSIP (Delta Sleep-Inducing Peptide)
You worked out the draw. Now log this dose.
A calculator answers once and forgets. Dosavy keeps the concentration you mixed, the doses you actually took, and a reminder for the next one, with the same evidence labels you see on this page.